The discussion about podoplanin and its participation in odontogenic tumours is a very recent topic of study, and the present results showed that podoplanin expression is strong in epithelium of the odontogenic tumours but it is negative in the ectomesenchyme and quiescent and more matures structures. This pattern of expression suggests that podoplanin expression is required during processes demanding high cellular activities such as proliferation and differentiation. In odontogenic tumours with and without ectomesenchyme, the podoplanin seems to participate
on the process of local invasion of such neoplasias probably orchestrating the cytoskeleton movement. This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP – grants #2005/04577-4 and 2007/04907-02005) and by Conselho Nacional Olaparib manufacturer de Desenvolvimento
Científico e Tecnológico (CNPq grant #500991/2010-3). The authors declare that they do not have any conflict of interest. This study was approved by the Human Research Ethics Committee from Bauru School of Dentistry, University of São Paulo. The process number is 099/2010. This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP – grants #2005/04577-4 and 2007/04907-02005) and by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq grant #500991/2010-3). The authors thank Fátima Aparecida Silveira Camargo for technical support and Dr José Roberto Pereira Lauris for statistical analysis. “
“Bisphosphonates HIF inhibitor are a class of synthetic analogs of pyrophosphate, which have been widely used in treatment of diseases with intense bone activity resorption, such as osteoporosis, Paget’s disease and some bone tumours, such as multiple myeloma, and bone metastases of breast and prostate tumours.1 and 2 These drugs are physiological modulators of bone
resorption and calcification with high affinity for hydroxyapatite crystals, thus remaining adhered to the mineralized tissues of body.3 and 4 In the same way as the bone tissue, dentin is characterized as a partially mineralized connective tissue with great hydroxyapatite content, and recent studies have been suggested that bisphosphonates can also adhere IMP dehydrogenase to this dental tissue.5 However, to date, little is known about how bisphosphonates adhere to the dental tissues, the mechanisms by which this adherence occurs or the conditions under which these drugs are released to the pulp. In vivo studies have demonstrated that treatment with bisphosphonates during the formation of teeth was associated with the occurrence of amelogenesis imperfecta and formation of a disorganized dentin tissue. 6 and 7 Sakai et al. 6 reported that bisphosphonates can adhere to dentin, promoting a complete or intermittent inhibition of dentinogenesis. It has been described that bisphosphonates can be released from mineralized tissues during bone resorption or remodelling.